real-time news and commentary for investors
Friday, Aug 16
Mannkind slips on cautious note out of Summer Street
- Mannkind (MNKD -7.1%) slips on a negative note out of Summer Street this morning.
- The firm appears to be suspicious of the results of the drug developer's Phase III AFFINITY 1 trial, after they released results on the injectable insulin and Dreamboat arms but withheld the results on the Medtone C-arm.
- Releasing data on only two of the three arms of the trial like that is unprecedented.
- If the results on the Medtone C-arm aren't worthy of presenting and inhalers aren't equivalent, then Summer Street feels there's not enough safety information to approve Dreamboat.